Micafungin Sandoz (Micafungin)

Micafungin is an echinocandin antifungal that disrupts fungal cell wall synthesis and is indicated for the following conditions:

• Invasive candidiasis: systemic treatment of bloodstream and deep‑tissue Candida infections, achieving clearance of fungal organisms in both adult and pediatric patients.
• Esophageal candidiasis: targeted therapy to eradicate Candida infection of the esophagus, relieving dysphagia and preventing complications in immunocompromised individuals.
• Prophylaxis of Candida infections in hematopoietic stem cell transplantation: preventive administration to reduce the incidence of invasive candidiasis in patients undergoing HSCT, supporting transplant success.

• Micafungin exerts its antifungal activity by selectively inhibiting the enzyme β‑(1,3)‑D‑glucan synthase, which is essential for the synthesis of β‑(1,3)‑D‑glucan, a critical structural component of the fungal cell wall. The resulting deficiency weakens the cell wall, leading to osmotic instability and fungicidal death of susceptible Candida species. This mechanism is specific to fungi and does not affect human cells, providing a favorable safety profile.

Micafungin may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects

• Fever: transient elevation of body temperature during or after infusion.
• Nausea: mild to moderate sensation of stomach upset.
• Elevated liver enzymes: increase in ALT/AST observed in laboratory tests.
• Headache: mild headache reported during treatment.

Serious or Rare Side Effects

• Hepatic failure: severe liver injury requiring medical intervention.
• Anaphylaxis: acute, potentially life‑threatening hypersensitivity reaction.
• Stevens‑Johnson syndrome: severe skin and mucous membrane disorder.
• Renal impairment: acute kidney injury in susceptible patients.

Prior to initiating Micafungin therapy, clinicians should consider several precautionary measures to ensure patient safety.

• Renal function: assess and monitor in patients with existing renal impairment.
• Hepatic function: evaluate liver enzymes before treatment and monitor periodically.
• Pregnancy: use only when the potential benefit justifies the potential risk to the fetus.
• Drug interactions: review concomitant medications for possible interactions.
• Infusion monitoring: administer under medical supervision and observe for infusion‑related reactions.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines; understanding the interaction potential helps optimize therapy.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce micafungin exposure.
• Concurrent use of other echinocandins: duplicate antifungal therapy should be avoided.

Moderate Interactions (Monitor Closely)

• Azole antifungals (e.g., fluconazole): may increase risk of hepatotoxicity; monitor liver function.
• Immunosuppressants (e.g., cyclosporine, tacrolimus): may require dose adjustment and level monitoring.
• Anticoagulants (e.g., warfarin): monitor INR for potential changes.
• QT‑prolonging agents: observe cardiac rhythm for additive effects.